.Kaufmann, P., Pariser, A. R. & Austin, C. From medical revelation to therapies for unusual diseasesu00e2 $" the view coming from the National Center for Evolving Translational Sciencesu00e2 $" Workplace of Rare Diseases Research Study. Orphanet J. Rare Dis. 13, 196 (2018 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T. A phone call to upper arms versus ultra-rare illness. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Vockley, J. et cetera. The developing duty of medical geneticists in the time of gene therapy: a necessity to prep. Genet. Med. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide treatment for a rare genetic disease. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kim, J. et al. A structure for individualized splice-switching oligonucleotide therapy. Structure 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lima, W. F. et cetera. Human RNase H1 evaluates in between refined variants in the design of the heteroduplex substrate. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X.-H. Antisense innovation: a guide as well as syllabus. Nat. Rev. Medication Discov. 20, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lee, J.-R. et cetera. De novo mutations in the motor domain of KIF1A trigger intellectual problems, spastic paraparesis, axonal neuropathy, as well as cerebellar degeneration. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Boyle, L. et cetera. Genotype and also defects in microtubule-based motility correlate along with scientific intensity in KIF1A-associated neurological ailment. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Electric motor protein KIF1A is actually important for hippocampal synaptogenesis as well as learning enhancement in an enriched environment. Nerve cell 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Guo, Y. et al. An unusual KIF1A missense anomaly boosts synaptic function and also raises confiscation activity. Front end. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kaur, S. et cetera. Growth of the phenotypic sphere of de novo missense variants in kinesin family member 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Canivez, G. L. & McGill, R. J. Aspect framework of the Differential Ability Scales-Second Version: exploratory as well as hierarchical element analyses with the primary subtests. Psychol. Assess. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Epstein, A. et cetera. Material validation of the lifestyle inventoryu00e2 $" impairment. Child Care Health Dev. 45, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Lek, M. et cetera. Evaluation of protein-coding genetic variation in 60,706 people. Attributes 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medicine Products for Severely Debilitating or even Severe Conditions: Clinical Recommendations (US Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Articles for Customized Antisense Oligonucleotide Medicine Products: Managerial and Step-by-step Suggestions Assistance for Sponsor-Investigators (United States Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Medication Use Entries for Customized Antisense Oligonucleotide Medicine Products for Significantly Devastating or even Serious Ailments: Chemistry, Production, as well as Controls Recommendations, Direction for Sponsor-Investigators (United States Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Significantly Debilitating or even Serious Diseases Advice for Sponsor-Investigators (US Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.